0	8	Anti-CD2	anti-cd2	NN
9	17	receptor	receptor	NN
18	28	antibodies	antibody	NNS
29	37	activate	activate	VBP
38	41	the	the	DT
42	45	HIV	HIV	NNP
46	50	long	long	JJ
51	59	terminal	terminal	JJ
60	66	repeat	repeat	NN
67	69	in	in	IN
70	71	T	t	NN
72	83	lymphocytes	lymphocyte	NNS
83	84	.	.	.

86	89	The	the	DT
90	93	CD2	cd2	NN
94	95	T	t	NN
96	106	lymphocyte	lymphocyte	NN
107	119	glycoprotein	glycoprotein	NN
120	127	surface	surface	NN
128	136	molecule	molecule	NN
137	145	mediates	mediate	VBZ
146	150	both	both	DT
151	155	cell	cell	NN
156	158	to	to	TO
159	163	cell	cell	NN
164	172	adhesion	adhesion	NN
173	176	and	and	CC
177	178	T	t	NN
179	183	cell	cell	NN
184	194	activation	activation	NN
194	195	,	,	,
196	199	two	two	CD
200	209	processes	process	NNS
210	214	that	that	WDT
215	218	are	be	VBP
219	227	involved	involve	VBN
228	230	in	in	IN
231	234	the	the	DT
235	241	spread	spread	NN
242	244	of	of	IN
245	248	HIV	HIV	NNP
249	258	infection	infection	NN
258	259	.	.	.

260	269	Treatment	Treatment	NNP
270	272	of	of	IN
273	284	chronically	chronically	RB
285	297	HIV-infected	hiv-infected	JJ
298	302	PBMC	PBMC	NNP
303	307	with	with	IN
308	316	anti-CD2	anti-cd2	JJ
317	320	mAb	mab	NN
321	324	has	have	VBZ
325	329	been	be	VBN
330	335	shown	show	VBN
336	338	to	to	TO
339	345	induce	induce	VB
346	349	the	the	DT
350	360	expression	expression	NN
361	363	of	of	IN
364	374	infectious	infectious	JJ
375	380	virus	virus	NN
381	385	from	from	IN
386	391	these	these	DT
392	400	cultures	culture	NNS
400	401	.	.	.

402	404	In	in	IN
405	409	this	this	DT
410	415	study	study	NN
416	418	we	we	PRP
419	431	investigated	investigate	VBD
432	435	the	the	DT
436	446	mechanisms	mechanism	NNS
447	454	whereby	whereby	WRB
455	463	anti-CD2	anti-cd2	JJ
464	474	antibodies	antibody	NNS
475	484	stimulate	stimulate	VBP
485	490	viral	viral	JJ
491	501	production	production	NN
501	502	.	.	.

503	505	We	we	PRP
506	517	demonstrate	demonstrate	VBP
518	522	that	that	IN
523	532	treatment	treatment	NN
533	535	of	of	IN
536	547	transiently	transiently	RB
548	559	transfected	transfecte	VBN
560	561	T	t	NN
562	573	lymphocytes	lymphocyte	NNS
574	578	with	with	IN
579	587	anti-CD2	anti-cd2	JJ
588	598	antibodies	antibody	NNS
599	606	results	result	VBZ
607	609	in	in	IN
610	620	activation	activation	NN
621	623	of	of	IN
624	627	the	the	DT
628	631	HIV	HIV	NNP
632	636	long	long	JJ
637	645	terminal	terminal	JJ
646	652	repeat	repeat	NN
652	653	.	.	.

654	665	Furthermore	furthermore	RB
665	666	,	,	,
667	670	CAT	CAT	NNP
671	677	assays	assay	NNS
678	683	using	use	VBG
684	691	mutated	mutate	VBN
692	695	HIV	HIV	NNP
696	700	long	long	JJ
701	709	terminal	terminal	JJ
710	720	repeat-CAT	repeat-cat	NN
721	731	constructs	construct	NNS
732	735	and	and	CC
736	739	gel	gel	NN
740	745	shift	shift	NN
746	752	assays	assay	NNS
753	764	demonstrate	demonstrate	VBP
765	769	that	that	IN
770	774	this	this	DT
775	785	activation	activation	NN
786	788	is	be	VBZ
789	798	dependent	dependent	JJ
799	801	on	on	IN
802	805	the	the	DT
806	814	NF-kappa	NF-kappa	NNP
815	816	B	B	NNP
817	825	enhancer	enhancer	NN
825	826	.	.	.

827	832	These	these	DT
833	840	studies	study	NNS
841	848	suggest	suggest	VBP
849	853	that	that	IN
854	865	interaction	interaction	NN
866	868	of	of	IN
869	872	CD2	cd2	NN
873	877	with	with	IN
878	881	its	its	PRP$
882	889	natural	natural	JJ
890	896	ligand	ligand	NN
896	897	,	,	,
898	903	LFA-3	LFA-3	NNP
903	904	,	,	,
905	908	may	may	MD
909	913	play	play	VB
914	915	a	a	DT
916	920	role	role	NN
921	923	in	in	IN
924	934	regulation	regulation	NN
935	937	of	of	IN
938	941	HIV	HIV	NNP
942	952	expression	expression	NN
952	953	.	.	.